KR102663134B1 - 생성 셀라인 인핸서 - Google Patents
생성 셀라인 인핸서 Download PDFInfo
- Publication number
- KR102663134B1 KR102663134B1 KR1020237014681A KR20237014681A KR102663134B1 KR 102663134 B1 KR102663134 B1 KR 102663134B1 KR 1020237014681 A KR1020237014681 A KR 1020237014681A KR 20237014681 A KR20237014681 A KR 20237014681A KR 102663134 B1 KR102663134 B1 KR 102663134B1
- Authority
- KR
- South Korea
- Prior art keywords
- leu
- ser
- delete delete
- gly
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2477—Hemicellulases not provided in a preceding group
- C12N9/2488—Mannanases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Cell Biology (AREA)
Abstract
Description
| 동물 | SEQ ID NO: | %동일성 사람 | %동일성 마우스 | %동일성 햄스터 |
| 마우스 | 1 | 93 | 100 | 96 |
| 쥐 | 2 | 94 | 98 | 96 |
| 햄스터 | 3 | 93 | 96 | 100 |
| 사람 | 4 | 100 | 93 | 93 |
| 침팬지 | 5 | 99 | 94 | 93 |
| 오랑우탄 | 6 | 97 | 92 | 92 |
| 제브라피시 | 7 | 69 | 70 | 69 |
| 공통 | 8 | 100 | 100 | 100 |
| 동물 | SEQ ID NO | %동일성 사람 | %동일성 마우스 | %동일성 햄스터 |
| 마우스 | 9 | 86 | 100 | 92 |
| 햄스터 | 10 | 86 | 92 | 100 |
| 사람 | 11 | 100 | 86 | 86 |
| 제브라피시 | 12 | 47 | 47 | 48 |
| 공통 | 13 | 100 | 100 | 100 |
| 명칭 | 인핸서 | 구성물 | 단백질 |
| C1 | EDEM2 + XBP1 | HC/LC = p1/p2 EDEM2 = p3 XBP1 = p4 |
aAng2 |
| C2 | XBP1 | ||
| C3 | EDEM2 + XBP1 | HC/LC = p5/p6 EDEM2 = p7 XBP1 = p4 |
aGDF8 |
| C4 | XBP1 | ||
| C5 | EDEM2 | ||
| C6 | EDEM2 + XBP1 | HC/LC = p8/p9 EDEM2 = p3 XBP1 = p4 |
aAngPtl4 |
| C7 | XBP1 |
| 셀라인 | 인핸서 | 생성률(pg/세포/일) | 역가 g/L (% 증가) |
| C1 | EDEM2 + XBP1 | 39 | 8.1 (93) |
| C2 | XBP1 | 39 | 4.2 |
| C3 | EDEM2 + XBP1 | 37 | 5.9 (55) |
| C8 | XBP1 | 32 | 3.8 |
| C6 | EDEM2 + XBP1 | 94 | 5.3 (152) |
| C7 | XBP1 | 52 | 2.1 |
| C5 | EDEM2 | 29 | 3.1 (343) |
| C9 | --- | 9 | 0.7 |
| 셀라인 | 인핸서 | ICD 106 세포-일/mL (% 증가) |
| C1 | EDEM2 + XBP1 | 205 (93) |
| C2 | XBP1 | 106 |
| C3 | EDEM2 + XBP1 | 157 (34) |
| C4 | XBP1 | 117 |
| C6 | EDEM2 + XBP1 | 56 (51) |
| C7 | XBP1 | 37 |
| C5 | EDEM2 | 116 (59) |
| C9 | --- | 73 |
| 역가 Bins (g/L) | ICD Bins (106 세포-일/mL) | ||||||
| 구성물 | <1 | 1-3 | 3-5 | 5-6 | 30-50 | 50-100 | 100-200 |
| E+X | 0% | 33.3% | 44.4% | 22.2% | 11.1% | 50% | 38.9% |
| X | 0% | 37.5% | 54% | 8.3% | 14.3% | 85.7% | 0% |
| E | 0% | 33% | 60% | 7% | 0% | 27% | 73% |
| - | 82% | 18% | 0% | 0% | 13% | 67% | 21% |
Claims (135)
- 분리된 포유류 세포로서,
SEQ ID NO: 8의 아미노산 서열 또는 SEQ ID NO: 1에 적어도 92% 동일한 아미노산 서열을 포함하는 소포체 분해-증강 알파-만노시다제-유사 단백질 2 (EDEM2)을 코드화하는 제1 폴리뉴클레오티드,
항체 중쇄를 코드화하는 제2 폴리뉴클레오티드, 및
항체 경쇄를 코드화하는 제3 폴리뉴클레오티드
를 포함하며,
EDEM2를 코드화하는 상기 제1 폴리뉴클레오티드는 구성성 프로모터에 작동가능하게 연결된, 세포. - 제1 항에 있어서, EDEM2는 SEQ ID NO: 8의 아미노산 서열을 포함하는 것을 특징으로 하는 세포.
- 제1 항에 있어서, EDEM2는 SEQ ID NO: 1에 적어도 92% 동일한 아미노산 서열을 포함하는 것을 특징으로 하는 세포.
- 제1 항에 있어서, EDEM2는 SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 및 SEQ ID NO: 6으로 구성된 군으로부터 선택된 아미노산 서열을 포함하는 것을 특징으로 하는 세포.
- 제1 항에 있어서, 항체 경쇄는 SEQ ID NO: 45의 아미노산 서열 및/또는 SEQ ID NO: 46의 아미노산 서열을 포함하는 것을 특징으로 하는 세포.
- 제1 항에 있어서, 항체 중쇄는 SEQ ID NO: 43의 아미노산 서열 및/또는 SEQ ID NO: 44의 아미노산 서열을 포함하는 것을 특징으로 하는 세포.
- 제1 항에 있어서, XBP-1의 스플라이싱 형태를 코드화하는 제4 폴리뉴클레오티드를 더 포함하는 것을 특징으로 하는 세포.
- 제7 항에 있어서, XBP-1의 스플라이싱 형태는 SEQ ID NO: 9에 적어도 86% 동일한 아미노산 서열을 포함하는 것을 특징으로 하는 세포.
- 제7 항에 있어서, XBP-1의 스플라이싱 형태는 SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 및 SEQ ID NO: 13으로 구성된 군으로부터 선택된 아미노산 서열을 포함하는 것을 특징으로 하는 세포.
- 제1 항에 있어서, 세포는 CHO 세포인 것을 특징으로 하는 세포.
- 제1 항 내지 제10 항 중 어느 한 항의 세포로부터 유도된 셀라인.
- 항체 제조 방법으로서 제1 항 내지 제10 항 중 어느 한 항의 세포를 배지에서 배양하는 단계를 포함하며, 항체 중쇄 및 항체 경쇄를 포함하는 항체가 세포에 의해 배지 안으로 분비되는, 방법.
- 제12 항에 있어서, 분비된 항체를 배지로부터 정제하는 단계를 더 포함하는 것을 특징으로 하는 방법.
- 분리된 포유류 세포로서
a. X-박스 결합 단백질 1 (XBP1)이고 SEQ ID NO: 9에 적어도 92% 동일한 아미노산 서열을 포함하는 제1 생성 인핸서 단백질을 코드화하는 핵산 서열을 포함하는 제1 폴리뉴클레오티드로서, 제1 생성 인핸서 단백질을 코드화하는 핵산 서열에 작동가능하게 연결된 구성성 프로모터를 더 포함하는 제1 폴리뉴클레오티드;
b. 항체 중쇄를 코드화하는 핵산 서열을 포함하는 제2 폴리뉴클레오티드; 및
c. 항체 경쇄를 코드화하는 핵산 서열을 포함하는제3 폴리뉴클레오티드
를 포함하는, 세포. - 제14 항에 있어서, 구성성 프로모터는 유비퀴틴 C 프로모터, CMV-IE 프로모터, 및 SV40 프로모터로 구성된 군으로부터 선택되는 것을 특징으로 하는 세포.
- 제14 항에 있어서, 제1 폴리뉴클레오티드는 세포의 전사적으로 활성인 유전자좌에서 통합되는 것을 특징으로 하는 세포.
- 제14 항에 있어서, 제1 생성 인핸서 단백질은 SEQ ID NO: 13, SEQ ID NO: 9, 및 SEQ ID NO: 10으로 구성된 군으로부터 선택된 아미노산 서열을 포함하는 것을 특징으로 하는 세포.
- 제14 항에 있어서, 세포는 소포체 분해-증강 알파-만노시다제-유사 단백질 2 (EDEM2)이고 SEQ ID NO: 1에 적어도 92% 동일한 아미노산 서열을 포함하는 제2 생성 인핸서 단백질을 코드화하는 핵산 서열을 포함하는 제4 폴리뉴클레오티드를 더 포함하는 것을 특징으로 하는 세포.
- 제18 항에 있어서, 제4 폴리뉴클레오티드는 제2 생성 인핸서 단백질을 코드화하는 핵산 서열에 작동가능하게 연결된 구성성 프로모터를 더 포함하는 것을 특징으로 하는 세포.
- 제19 항에 있어서, 제4 폴리뉴클레오티드 내의 구성성 프로모터는 유비퀴틴 C 프로모터, CMV-IE 프로모터, 및 SV40 프로모터로 구성된 군으로부터 선택되는 것을 특징으로 하는 세포.
- 제18 항에 있어서, 제2 생성 인핸서 단백질은 SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, 및 SEQ ID NO: 8로 구성된 군으로부터 선택된 아미노산 서열을 포함하는 것을 특징으로 하는 세포.
- 제14 항에 있어서, 항체는 SEQ ID NO: 46의 아미노산 서열을 포함하는 경쇄를 포함하는 것을 특징으로 하는 세포.
- 제14 항에 있어서, 항체는 SEQ ID NO: 44의 아미노산 서열을 포함하는 중쇄를 포함하는 것을 특징으로 하는 세포.
- 제14 항에 있어서, 세포는 CHO 세포인 것을 특징으로 하는 세포.
- 제14 항 내지 제24 항 중 어느 한 항의 세포로부터 클론 팽창에 의해 유래된 다수의 세포를 포함하는 셀라인.
- 항체 제조 방법으로서
a. 제14 항 내지 제24 항 중 어느 한 항의 세포로부터 클론 팽창에 의해 유래된 다수의 세포를 배지에서 배양하는 단계;
b. 세포가 항체를 배지 안으로 분비할 수 있게 하는 단계; 및
c. 항체를 배지로부터 정제하는 단계
를 포함하는 방법. - 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261652549P | 2012-05-29 | 2012-05-29 | |
| US61/652,549 | 2012-05-29 | ||
| US13/904,587 | 2013-05-29 | ||
| US13/904,587 US9079954B2 (en) | 2012-05-29 | 2013-05-29 | Production cell line enhancers |
| PCT/US2013/043116 WO2013181253A1 (en) | 2012-05-29 | 2013-05-29 | Production cell line enhancers |
| KR1020217043208A KR102528950B1 (ko) | 2012-05-29 | 2013-05-29 | 생성 셀라인 인핸서 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217043208A Division KR102528950B1 (ko) | 2012-05-29 | 2013-05-29 | 생성 셀라인 인핸서 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230065370A KR20230065370A (ko) | 2023-05-11 |
| KR102663134B1 true KR102663134B1 (ko) | 2024-05-03 |
Family
ID=49670701
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207017417A Active KR102346867B1 (ko) | 2012-05-29 | 2013-05-29 | 생성 셀라인 인핸서 |
| KR1020217043208A Active KR102528950B1 (ko) | 2012-05-29 | 2013-05-29 | 생성 셀라인 인핸서 |
| KR1020147033930A Active KR102126210B1 (ko) | 2012-05-29 | 2013-05-29 | 생성 셀라인 인핸서 |
| KR1020237014681A Active KR102663134B1 (ko) | 2012-05-29 | 2013-05-29 | 생성 셀라인 인핸서 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207017417A Active KR102346867B1 (ko) | 2012-05-29 | 2013-05-29 | 생성 셀라인 인핸서 |
| KR1020217043208A Active KR102528950B1 (ko) | 2012-05-29 | 2013-05-29 | 생성 셀라인 인핸서 |
| KR1020147033930A Active KR102126210B1 (ko) | 2012-05-29 | 2013-05-29 | 생성 셀라인 인핸서 |
Country Status (20)
| Country | Link |
|---|---|
| US (9) | US9079954B2 (ko) |
| EP (3) | EP3564262A1 (ko) |
| JP (5) | JP6298455B2 (ko) |
| KR (4) | KR102346867B1 (ko) |
| CN (2) | CN110835624A (ko) |
| AU (4) | AU2013267525B2 (ko) |
| BR (1) | BR112014029095A2 (ko) |
| CA (1) | CA2873131A1 (ko) |
| DK (1) | DK2875047T5 (ko) |
| EA (2) | EA028790B1 (ko) |
| ES (1) | ES2940900T3 (ko) |
| FI (1) | FI2875047T3 (ko) |
| HU (1) | HUE061479T2 (ko) |
| IL (4) | IL320011A (ko) |
| MX (1) | MX360359B (ko) |
| PL (1) | PL2875047T3 (ko) |
| SG (2) | SG10201606654XA (ko) |
| TW (2) | TW201823460A (ko) |
| WO (1) | WO2013181253A1 (ko) |
| ZA (1) | ZA201408289B (ko) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| US11530277B2 (en) | 2016-04-20 | 2022-12-20 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| WO2017184832A1 (en) | 2016-04-20 | 2017-10-26 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of expression-enhancing loci |
| ES2987333T3 (es) * | 2016-10-26 | 2024-11-14 | Univ Leland Stanford Junior | Regiones bisagra de inmunoglobulina modificadas para reducir la hemaglutinación |
| CA3043487A1 (en) | 2016-11-21 | 2018-05-24 | Just Biotherapeutics, Inc. | Aflibercept formulations and uses thereof |
| CN111344410B (zh) | 2017-08-17 | 2023-09-15 | 济世易为生物有限公司 | 从宿主细胞半乳糖凝集素和其他污染物中纯化糖基化蛋白的方法 |
| WO2019099965A1 (en) | 2017-11-20 | 2019-05-23 | Just Biotherapeutics, Inc. | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009062789A1 (en) | 2007-11-13 | 2009-05-22 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Improving the secretory capacity in host cells |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4323167B2 (ja) | 2001-01-16 | 2009-09-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 分泌タンパク質を発現する細胞の単離 |
| WO2003101189A1 (en) | 2002-05-29 | 2003-12-11 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| AU2003268356A1 (en) | 2002-08-30 | 2004-03-19 | President And Fellows Of Harvard College | Methods and compositions for modulating xbp-1 activity |
| JP2007500016A (ja) * | 2003-06-11 | 2007-01-11 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 培養においてタンパク質生成を増大させるための方法 |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| JP2007537728A (ja) * | 2004-03-31 | 2007-12-27 | セントカー・インコーポレーテツド | タンパク質生産速度の変更方法 |
| KR20070061524A (ko) * | 2004-07-20 | 2007-06-13 | 제넨테크, 인크. | 안지오포이에틴-유사 4 단백질을 사용하는 조성물 및 방법 |
| CN101048509A (zh) | 2004-09-02 | 2007-10-03 | 惠氏公司 | 用于产生蛋白质的体系和方法 |
| WO2006031931A2 (en) | 2004-09-15 | 2006-03-23 | The President And Fellows Of Harvard College | Reducing er stress in the treatment of obesity and diabetes |
| EP1964922A1 (en) * | 2007-03-02 | 2008-09-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | Improvement of protein production |
| WO2008115596A2 (en) | 2007-03-21 | 2008-09-25 | Danisco Us, Inc., Genencor Division | Over expression of foldases and chaperones improves protein production |
| US7771997B2 (en) | 2007-06-04 | 2010-08-10 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| EP2185178B1 (en) * | 2007-08-03 | 2017-08-23 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
| PE20091163A1 (es) * | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| US20090247609A1 (en) * | 2007-12-20 | 2009-10-01 | Hitto Kaufmann | Sm-protein based secretion engineering |
| CA2726289A1 (en) * | 2008-05-28 | 2009-12-23 | Bayer Healthcare Llc | Methods and compositions for production of recombinant protein in hbx-expressing mammalian cells |
| US20110142799A1 (en) | 2008-06-23 | 2011-06-16 | President And Fellows Of Harvard College | Modulation of neurodegenerative disease by modulating xbp-1 activity |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| GB0902180D0 (en) * | 2009-02-10 | 2009-03-25 | Ucb Pharma Sa | Method for producing protein |
| WO2010117455A2 (en) * | 2009-04-08 | 2010-10-14 | U.S. Army Medical Research Institute Of Infectious Diseases | Human monoclonal antibodies protective against bubonic plaque |
| BRPI1010035A2 (pt) | 2009-06-02 | 2015-08-25 | Regeneron Pharma | Células deficientes em fucosilação |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| JO3274B1 (ar) * | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
| JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| WO2014071402A1 (en) | 2012-11-05 | 2014-05-08 | Dana-Farber Cancer Institute, Inc. | Xbp1, cd138, and cs1, pharmaceutical compositions that include the peptides, and methods of using such petides and compositions |
-
2013
- 2013-05-28 TW TW107107833A patent/TW201823460A/zh unknown
- 2013-05-28 TW TW102118721A patent/TWI641687B/zh active
- 2013-05-29 SG SG10201606654XA patent/SG10201606654XA/en unknown
- 2013-05-29 DK DK13729169.6T patent/DK2875047T5/da active
- 2013-05-29 JP JP2015515154A patent/JP6298455B2/ja active Active
- 2013-05-29 KR KR1020207017417A patent/KR102346867B1/ko active Active
- 2013-05-29 EA EA201492242A patent/EA028790B1/ru not_active IP Right Cessation
- 2013-05-29 EA EA201792213A patent/EA201792213A1/ru unknown
- 2013-05-29 CN CN201911104558.3A patent/CN110835624A/zh active Pending
- 2013-05-29 AU AU2013267525A patent/AU2013267525B2/en active Active
- 2013-05-29 BR BR112014029095A patent/BR112014029095A2/pt not_active Application Discontinuation
- 2013-05-29 MX MX2014014630A patent/MX360359B/es active IP Right Grant
- 2013-05-29 PL PL13729169.6T patent/PL2875047T3/pl unknown
- 2013-05-29 HU HUE13729169A patent/HUE061479T2/hu unknown
- 2013-05-29 EP EP19177521.2A patent/EP3564262A1/en not_active Withdrawn
- 2013-05-29 SG SG11201407652RA patent/SG11201407652RA/en unknown
- 2013-05-29 EP EP22214230.9A patent/EP4219546A3/en active Pending
- 2013-05-29 US US13/904,587 patent/US9079954B2/en active Active
- 2013-05-29 IL IL320011A patent/IL320011A/en unknown
- 2013-05-29 FI FIEP13729169.6T patent/FI2875047T3/fi active
- 2013-05-29 CN CN201380028164.9A patent/CN104350068B/zh active Active
- 2013-05-29 WO PCT/US2013/043116 patent/WO2013181253A1/en active Application Filing
- 2013-05-29 KR KR1020217043208A patent/KR102528950B1/ko active Active
- 2013-05-29 ES ES13729169T patent/ES2940900T3/es active Active
- 2013-05-29 KR KR1020147033930A patent/KR102126210B1/ko active Active
- 2013-05-29 EP EP13729169.6A patent/EP2875047B1/en active Active
- 2013-05-29 KR KR1020237014681A patent/KR102663134B1/ko active Active
- 2013-05-29 CA CA2873131A patent/CA2873131A1/en active Pending
-
2014
- 2014-11-09 IL IL235573A patent/IL235573B/en active IP Right Grant
- 2014-11-12 ZA ZA2014/08289A patent/ZA201408289B/en unknown
- 2014-11-26 US US14/555,220 patent/US9382315B2/en active Active
-
2015
- 2015-06-11 US US14/737,090 patent/US10227401B2/en active Active
- 2015-06-29 US US14/754,112 patent/US9193786B2/en active Active
- 2015-06-29 US US14/754,146 patent/US9228012B2/en active Active
-
2016
- 2016-07-01 US US15/201,104 patent/US9688751B2/en not_active Ceased
-
2017
- 2017-06-16 US US15/624,982 patent/US10351622B2/en active Active
-
2018
- 2018-02-14 AU AU2018201094A patent/AU2018201094B2/en active Active
- 2018-02-23 JP JP2018030324A patent/JP6622334B2/ja active Active
-
2019
- 2019-04-07 IL IL265867A patent/IL265867A/en unknown
- 2019-04-17 US US16/387,134 patent/USRE48651E1/en active Active
- 2019-05-21 US US16/417,792 patent/US10611831B2/en active Active
- 2019-05-30 AU AU2019203780A patent/AU2019203780B2/en active Active
- 2019-11-21 JP JP2019210124A patent/JP7037535B2/ja active Active
-
2021
- 2021-01-03 IL IL279922A patent/IL279922B2/en unknown
- 2021-10-01 AU AU2021240303A patent/AU2021240303B2/en active Active
- 2021-12-27 JP JP2021212131A patent/JP7382383B2/ja active Active
-
2023
- 2023-08-22 JP JP2023134346A patent/JP2023153268A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009062789A1 (en) | 2007-11-13 | 2009-05-22 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Improving the secretory capacity in host cells |
Non-Patent Citations (1)
| Title |
|---|
| J Biol Chem, 280(4):2424-2428(20025) |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021240303B2 (en) | Production cell line enhancers | |
| CN110023500B (zh) | 作为选择标记的减毒谷氨酰胺合成酶 | |
| CN101553506B (zh) | Lingo结合分子及其制药用途 | |
| KR102636351B1 (ko) | 고활성 조절 요소 | |
| KR101761709B1 (ko) | 부위 특이적 통합 | |
| KR102799185B1 (ko) | 아마이엘로이스로부터의 트랜스포사제를 이용한 핵산 작제물의 진핵세포 게놈으로의 전위 | |
| CN109260478A (zh) | 通过序列特异性转肽酶制备免疫配体/效应分子结合物的方法 | |
| KR20080031024A (ko) | 폴리단백질, 프로단백질 및 단백질분해를 사용한 sORF작제물 포함 다중 유전자 발현 및 방법 | |
| AU2024200154A1 (en) | An engineered multi-component system for identification and characterisation of T-cell receptors, T-cell antigens and their functional interaction | |
| CN101287498A (zh) | Psma抗体-药物缀合物 | |
| KR20070002052A (ko) | IL-15/Fc 융합 단백질의 제조를 위한 발현 시스템 및이의 용도 | |
| CN101208425A (zh) | 产生复制缺陷型腺病毒的细胞系 | |
| KR20230056630A (ko) | 신규의 omni-59, 61, 67, 76, 79, 80, 81 및 82 crispr 뉴클레아제 | |
| CN107207603A (zh) | 趋化因子‑免疫球蛋白融合多肽,其组合物、制备方法以及用途 | |
| CN1946739A (zh) | 纯化的白细胞介素-15/Fc融合蛋白及其制备 | |
| KR20230117327A (ko) | 가용성 알칼리성 포스파타제 작제물 및 가용성 알칼리성 포스파타제 작제물을 인코딩하는 폴리뉴클레오티드를 포함하는 발현 벡터 | |
| KR20240021906A (ko) | 발현 벡터, 박테리아 서열-무함유 벡터, 및 이를 제조하고 사용하는 방법 | |
| CN101160139A (zh) | 含有pedf以及fgf2的伴随眼组织细胞凋亡变性的疾患的治疗药物 | |
| CN117881788A (zh) | 表达载体、无细菌序列载体及其制备和使用方法 | |
| CN110777147A (zh) | 一种ikzf3基因沉默的t细胞及其应用 | |
| HK40067445A (en) | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme | |
| HK40003571A (en) | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme | |
| KR20070018054A (ko) | 정제된 인터루킨-15/Fc융합 단백질 및 이의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20230428 Application number text: 1020217043208 Filing date: 20211230 |
|
| PG1501 | Laying open of application | ||
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20240131 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240429 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240430 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |